Clinical Trials Logo

Anaplastic Lymphoma Kinase clinical trials

View clinical trials related to Anaplastic Lymphoma Kinase.

Filter by:
  • None
  • Page 1

NCT ID: NCT04887519 Completed - Clinical trials for Carcinoma, Non-Small-Cell Lung

A Study of Brigatinib to Treat Adults With Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non Small Cell Lung Cancer (NSCLC)

Start date: December 30, 2020
Phase:
Study type: Observational

The aims of the study are to assess the safety profile of brigatinib and the clinical response rates in adults with Anaplastic Lymphoma Kinase (ALK)-Positive Metastatic Non Small Cell Lung Cancer (NSCLC). Treatment with brigatinib and follow-up will be according to routine clinical practice. Study doctors will review the participants' medical records at the start of the study, then at 12 and 24 weeks after treatment starts.

NCT ID: NCT04592523 Recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea

Start date: September 5, 2019
Phase:
Study type: Observational

The purpose of this study is to estimate the proportion of all adverse events (AEs) including serious adverse events (SAEs) occurring with the use of brigatinib among adult participants who have been administered brigatinib as per the approved indications.